Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Switzerland's Vifor strikes kidney drug deal with Angion

11/09/2020 | 04:44am EST

ZURICH, Nov 9 (Reuters) - Swiss drugmaker Vifor Pharma on Monday agreed to pay United States-based Angion Biomedica up to $80 million for rights to experimental kidney drug ANG-3777.

Angion's ANG-3777 is in late-stage trials to determine whether it helps kidney transplant patients at risk of impaired functioning of the donated organ. It is also in an earlier-stage study for acute kidney injury associated with cardiac surgery.

The licensing deal includes a $30 million up-front payment, a $30 million equity investment in Angion and $20 million in milestone payments, as well as up to $260 million in other milestones upon U.S. and EU approval. Further royalties are also possible, the Swiss company said.

Vifor is seeking to boost its nephrology portfolio, where it already has drugs in trials for anaemia due to chronic kidney disease and vasculitis. The company also has a joint venture with Germany's Fresenius to provide products and services for chronic kidney disease patients.

Data from the trial of ANG-3777 in patients with transplant-associated acute kidney injury is due in the second half of next year. The Angion deal with Vifor excludes China, where the U.S. company already has a pact with Sinovant Sciences. (Reporting by John Miller Editing by David Goodman)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA -0.29% 68.78 Delayed Quote.0.85%
FRESENIUS SE & CO. KGAA -1.31% 38.39 Delayed Quote.1.45%
VIFOR PHARMA -0.65% 136.6 Delayed Quote.-1.73%
All news about VIFOR PHARMA
2020ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..
2020VIFOR PHARMA : VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Tri..
2020Octavian Lowers Price Target on Vifor Pharma, Maintains Buy Recommendation
2020Swiss drugmaker Vifor had bid interest but talks halted - sources
2020MARKET CHATTER : Vifor Pharma Rejects $11 Billion Offer, Other Bids; Stock Up 7%
2020VIFOR PHARMA : supports Iron Deficiency Day 2020 to highlight global impact on h..
2020Research Partners Maintains Price Target on Vifor Pharma, Initiates Coverage ..
2020VIFOR PHARMA : VFMCRP and Fresenius Kabi expand collaboration in nephrology in C..
2020VIFOR PHARMA : Full results from affirm-ahf study show ferinject significantly r..
2020Vifor Pharma Study for Ferinject Shows Reduction in Hospitalizations of Heart..
More news
Sales 2020 1 845 M 2 069 M 2 069 M
Net income 2020 321 M 360 M 360 M
Net cash 2020 481 M 539 M 539 M
P/E ratio 2020 26,3x
Yield 2020 1,52%
Capitalization 8 864 M 9 962 M 9 942 M
EV / Sales 2020 4,55x
EV / Sales 2021 4,16x
Nbr of Employees 2 733
Free-Float 71,8%
Duration : Period :
Vifor Pharma Technical Analysis Chart | VIFN | CH0364749348 | MarketScreener
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 140,44 CHF
Last Close Price 136,60 CHF
Spread / Highest target 33,2%
Spread / Average Target 2,81%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
Stefan Schulze President, Chief Executive & Operating Officer
Jacques Theurillat Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Etienne Jornod Honorary Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA-1.73%9 962
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993